Literature DB >> 29220112

Multispectral image analysis in Vogt-Koyanagi-Harada disease.

Guo Huang1, Junchao Peng1, Zi Ye1, Aize Kijlstra2, Donglei Zhang1, Peizeng Yang1.   

Abstract

PURPOSE: To investigate fundus abnormalities in Vogt-Koyanagi-Harada (VKH) disease by a noninvasive tool, multispectral imaging (MSI).
METHODS: A total of 77 patients with VKH and 163 healthy controls were enrolled between January and April 2015. The MSI findings were evaluated in combination with fundus fluorescein angiography (FFA), optical coherent tomography (OCT) and fundus photography (FP). Additionally, we compared extent of exposure of choroidal blood vessels between patients with VKH and healthy controls to evaluate retinal transmission function.
RESULTS: A number of features could be recognized by MSI which included (i) general depigmentation, (ii) clumping of pigment and (iii) macular depigmentation and/or hyperpigmentation. The percentages of these three abnormalities discovered by MSI in 52 inactive VKH patients with a duration of more than 2 months in VKH were 67.3%, 75% and 84.6% respectively, which were all significantly higher than those detected by FFA, OCT or FP (p = 0.0398, p < 0.0001). Our study showed that MSI detected a higher percentages of these four abnormalities in patients with sunset glow fundus than in patients without this phenomenon (p = 0.0492, p < 0.0001). Additionally, at the same wavelength (590 nm), exposure of choroidal blood vessels in inactive patients was stronger than in healthy controls and active patients (p < 0.01, p < 0.001).
CONCLUSION: Our results show that MSI is a sensitive noninvasive method to investigate the retinal pigment epithelium (RPE) in VKH disease. It is more likely to detect RPE abnormalities with MSI than when using FFA, OCT or FP. Retinal transmission function in inactive patients is stronger than that observed in active patients or healthy controls.
© 2017 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Vogt-Koyanagi-Harada disease; multispectral imaging; retina; retinal pigment epithelium; retinal transmission function

Mesh:

Year:  2017        PMID: 29220112     DOI: 10.1111/aos.13606

Source DB:  PubMed          Journal:  Acta Ophthalmol        ISSN: 1755-375X            Impact factor:   3.761


  6 in total

1.  Melanin change of retinal pigment epithelium and choroid in the convalescent stage of Vogt-Koyanagi-Harada disease.

Authors:  Ying Huang; Ya-Ting Yang; Bing Lin; Sheng-Hai Huang; Zu-Hua Sun; Rong Zhou; Ying-Zi Li; Xiao-Ling Liu
Journal:  Int J Ophthalmol       Date:  2020-12-18       Impact factor: 1.779

Review 2.  Acute lymphocytic leukemia with initial manifestation of serous retinal detachment and choroidal thickening: case report and literature review.

Authors:  Weiming Yan; Yunpeng Wang; Xiangrong Zheng; Xiaohong Chen; Qian Ye; Yanjin Chen; Meizhu Chen
Journal:  J Int Med Res       Date:  2021-03       Impact factor: 1.671

3.  Retinal and choroidal abnormalities identified by multispectral imaging in patients with uveitis: Three case reports.

Authors:  Lei Feng; Gong-Lin Fan; Jie Zhang; Xiao Wang; Jiang Zhu
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

Review 4.  Vogt-Koyanagi-Harada disease: the step-by-step approach to a better understanding of clinicopathology, immunopathology, diagnosis, and management: a brief review.

Authors:  Cristhian A Urzua; Carl P Herbort; Masaru Takeuchi; Ariel Schlaen; Luz E Concha-Del-Rio; Yoshihiko Usui; Loreto Cuitino; Ioannis Papasavvas
Journal:  J Ophthalmic Inflamm Infect       Date:  2022-05-12

5.  Multi-spectral imaging in adult-onset foveomacular vitelliform dystrophy: Report of two cases.

Authors:  Mingzhen Yuan; Feiyan Ma; Lulu Chen; Youxin Chen
Journal:  Am J Ophthalmol Case Rep       Date:  2022-04-21

6.  Clinical Comparative Study of Different Fundus Imaging Methods in the Acute Phase of Vogt-Koyanagi-Harada Disease.

Authors:  Hongyun Wu; Liqun Hu; Wei Tang; Guishang Chen; Jinrong Liu; Shaojun Li; Zhe Xu
Journal:  Evid Based Complement Alternat Med       Date:  2022-10-10       Impact factor: 2.650

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.